[1] A. Cekici, A. Kantarci, H. Hasturk, T.E. Van Dyke, Inflammatory and immune pathways in the pathogenesis of periodontal disease, Periodontology 2000 64 (2014) 57-80. 10.1111/prd.12002.
[2] J.A.F. Cestari, G.M.C. Fabri, J. Kalil, R. Nitrini, W. Jacob, J.T.T. de Siqueira, S. Siqueira, Oral Infections and Cytokine Levels in Patients with Alzheimer's Disease and Mild Cognitive Impairment Compared with Controls (vol 52, pg 1479, 2016), Journal of Alzheimers Disease 54 (2016) 845-845. 10.3233/jad-169006.
[3] R. Cacabelos, A. Meyyazhagan, J.C. Carril, P. Cacabelos, O. Teijido, Pharmacogenetics of Vascular Risk Factors in Alzheimer's Disease, Journal of Personalized Medicine 8 (2018) Unsp 3. 10.3390/jpm8010003.
[4] A. Jayaraman, C.J. Pike, Alzheimer's Disease and Type 2 Diabetes: Multiple Mechanisms Contribute to Interactions, Current Diabetes Reports 14 (2014) 476. 10.1007/s11892-014-0476-2.
[5] C. Reitz, Genetic diagnosis and prognosis of Alzheimer's disease: challenges and opportunities, Expert Review of Molecular Diagnostics 15 (2015) 339-348. 10.1586/14737159.2015.1002469.
[6] D.S. Rivera, N.C. Inestrosa, F. Bozinovic, On cognitive ecology and the environmental factors that promote Alzheimer disease: lessons from Octodon degus (Rodentia: Octodontidae), Biological Research 49 (2016) 10. 10.1186/s40659-016-0074-7.
[7] A.M. Tolppanen, H. Taipale, S. Hartikainen, Head or brain injuries and Alzheimer's disease: A nested case-control register study, Alzheimer's & dementia : the journal of the Alzheimer's Association 13 (2017) 1371-1379. 10.1016/j.jalz.2017.04.010.
[8] M. Vijayan, P.H. Reddy, Stroke, Vascular Dementia, and Alzheimer's Disease: Molecular Links, Journal of Alzheimers Disease 54 (2016) 427-443. 10.3233/jad-160527.
[9] W.V. Graham, A. Bonito-Oliva, T.P. Sakmar, Update on Alzheimer's Disease Therapy and Prevention Strategies, in: C.T. Caskey (Ed.) Annual Review of Medicine, Vol 682017, pp. 413-430.
[10] T. Barrett, S.E. Wilhite, P. Ledoux, C. Evangelista, I.F. Kim, M. Tomashevsky, K.A. Marshall, K.H. Phillippy, P.M. Sherman, M. Holko, A. Yefanov, H. Lee, N. Zhang, C.L. Robertson, N. Serova, S. Davis, A. Soboleva, NCBI GEO: archive for functional genomics data sets-update, Nucleic Acids Research 41 (2013) D991-D995. 10.1093/nar/gks1193.
[11] Y. Guo, Y. Bao, M. Ma, W. Yang, Identification of Key Candidate Genes and Pathways in Colorectal Cancer by Integrated Bioinformatical Analysis, International Journal of Molecular Sciences 18 (2017) 722. 10.3390/ijms18040722.
[12] G.K. Smyth, Limma: Linear models for microarray data, in: R. Gentalman, V.J. Carey, W. Huber, R.A. Irizarry, S. Dudoit (Eds.) Bioinformatics and Computational Biology Solution Using R and Bioconductor2005, pp. 397-420.
[13] J.S. Racine, RStudio: A Platform-Independent IDE for R and Sweave, Journal of Applied Econometrics 27 (2012) 167-172. 10.1002/jae.1278.
[14] J. Baran, M. Gerner, M. Haeussler, G. Nenadic, C.M. Bergman, pubmed2ensembl: A Resource for Mining the Biological Literature on Genes, Plos One 6 (2011) e24716. 10.1371/journal.pone.0024716.
[15] D.W. Huang, B.T. Sherman, R.A. Lempicki, Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources, Nature Protocols 4 (2009) 44-57. 10.1038/nprot.2008.211.
[16] C.M. Hooper, S.M. Hawes, U.R. Kees, N.G. Gottardo, P.B. Dallas, Gene Expression Analyses of the Spatio-Temporal Relationships of Human Medulloblastoma Subgroups during Early Human Neurogenesis, Plos One 9 (2014) e112909. 10.1371/journal.pone.0112909.
[17] R. Edgar, M. Domrachev, A.E. Lash, Gene Expression Omnibus: NCBI gene expression and hybridization array data repository, Nucleic Acids Research 30 (2002) 207-210. 10.1093/nar/30.1.207.
[18] A. Reiner, D. Yekutieli, Y. Benjamini, Identifying differentially expressed genes using false discovery rate controlling procedures, Bioinformatics 19 (2003) 368-375. 10.1093/bioinformatics/btf877.
[19] A. Franceschini, D. Szklarczyk, S. Frankild, M. Kuhn, M. Simonovic, A. Roth, J. Lin, P. Minguez, P. Bork, C. von Mering, L.J. Jensen, STRING v9.1: protein-protein interaction networks, with increased coverage and integration, Nucleic Acids Research 41 (2013) D808-D815. 10.1093/nar/gks1094.
[20] M. Shimada, I. Hernandez-Gonzalez, I. Gonzalez-Robayna, J.A.S. Richards, Paracrine and autocrine regulation of epidermal growth factor-like factors in cumulus oocyte complexes and granulosa cells: Key roles for prostaglandin synthase 2 and progesterone receptor, Molecular Endocrinology 20 (2006) 1352-1365. 10.1210/me.2005-0504.
[21] M. Hsieh, D. Lee, S. Panigone, K. Homer, R. Chen, A. Theologis, D.C. Lee, D.W. Threadgill, M. Conti, Luteinizing hormone-dependent activation of the epidermal growth factor network is essential for ovulation, Molecular and Cellular Biology 27 (2007) 1914-1924. 10.1128/mcb.01919-06.
[22] J.Y. Park, Y.Q. Su, M. Ariga, E. Law, S.L.C. Jin, M. Conti, EGF-like growth factors as mediators of LH action in the ovulatory follicle, Science 303 (2004) 682-684. 10.1126/science.1092463.
[23] S. Schubbert, K. Shannon, G. Bollag, Hyperactive Ras in developmental disorders and cancer, Nature Reviews Cancer 7 (2007) 295-308. 10.1038/nrc2109.
[24] K.J. Schmitz, J. Wohlschlaeger, H. Alakus, J. Bohr, M.A. Stauder, K. Worm, G. Winde, K.W. Schmid, H.A. Baba, Activation of extracellular regulated kinases (ERK1/2) but not AKT predicts poor prognosis in colorectal carcinoma and is associated with k-ras mutations, Virchows Archiv 450 (2007) 151-159. 10.1007/s00428-006-0342-y.
[25] L.M. Williams, G. Ricchetti, U. Sarma, T. Smallie, B.M.J. Foxwell, Interleukin-10 suppression of myeloid cell activation - a continuing puzzle, Immunology 113 (2004) 281-292. 10.1111/j.1365-2567.2004.01988.x.
[26] K. Strle, J.H. Zhou, W.H. Shen, S.R. Broussard, R.W. Johnson, G.G. Freund, R. Dantzer, K.W. Kelley, Interleukin-10 in the brain, Crit Rev Immunol 21 (2001) 427-449.
[27] M.O. Li, R.A. Flavell, Contextual regulation of inflammation: A duet by transforming growth factor-beta and interleukin-10, Immunity 28 (2008) 468-476. 10.1016/j.immuni.2008.03.003.
[28] M.V. Guillot-Sestier, K.R. Doty, D. Gate, J. Rodriguez, Jr., B.P. Leung, K. Rezai-Zadeh, T. Town, Il10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology, Neuron 85 (2015) 534-548. 10.1016/j.neuron.2014.12.068.
[29] K.F. Loewenbrueck, J.T. Tigno-Aranjuez, B.O. Boehm, P.V. Lehmann, M. Tary-Lehmann, Th1 responses to beta-amyloid in young humans convert to regulatory IL-10 responses in Down syndrome and Alzheimer's disease, Neurobiology of Aging 31 (2010) 1732-1742. 10.1016/j.neurobiolaging.2008.09.007.
[30] D. Culpan, J.A. Prince, S. Matthews, L. Palmer, A. Hughes, S. Love, P.G. Kehoe, G.K. Wilcock, Neither sequence variation in the IL-10 gene promoter nor presence of IL-10 protein in the cerebral cortex is associated with Alzheimer's disease, Neuroscience Letters 408 (2006) 141-145. 10.1016/j.neulet.2006.08.068.
[31] P. Angelopoulos, H. Agouridaki, H. Vaiopoulos, E. Siskou, K. Doutsou, V. Costa, S.I. Baloyiannis, CYTOKINES IN ALZHEIMER'S DISEASE AND VASCULAR DEMENTIA, International Journal of Neuroscience 118 (2008) 1659-1672. 10.1080/00207450701392068.
[32] M. Osaki, M. Oshimura, H. Ito, PI3K-Akt pathway: Its functions and alterations in human cancer, Apoptosis 9 (2004) 667-676. DOI 10.1023/B:APPT.0000045801.15585.dd.
[33] J. Folkman, Role of angiogenesis in tumor growth and metastasis, Semin Oncol 29 (2002) 15-18. 10.1053/sonc.2002.37263.
[34] J. Geng, X. Li, Z.M. Zhou, C.L. Wu, M. Dai, X.Y. Bai, EZH2 promotes tumor progression via regulating VEGF-A/AKT signaling in non-small cell lung cancer, Cancer Lett 359 (2015) 275-287. 10.1016/j.canlet.2015.01.031.
[35] H.B. Ma, J.S. Pan, L.X. Jin, J.F. Wu, Y.D. Ren, P.D. Chen, C.C. Xiao, J.H. Han, MicroRNA-17 similar to 92 inhibits colorectal cancer progression by targeting angiogenesis, Cancer Lett 376 (2016) 293-302. 10.1016/j.canlet.2016.04.011.
[36] L.P. Liu, N. Bi, L.H. Wu, X. Ding, Y. Men, W. Zhou, L. Li, W.M. Zhang, S.S. Shi, Y.M. Song, L.H. Wang, MicroRNA-29c functions as a tumor suppressor by targeting VEGFA in lung adenocarcinoma, Mol Cancer 16 (2017). ARTN 50
10.1186/s12943-017-0620-0.
[37] O.O. Ogunshola, A. Antic, M.J. Donoghue, S.Y. Fan, H. Kim, W.B. Stewart, J.A. Madri, L.R. Ment, Paracrine and autocrine functions of neuronal vascular endothelial growth factor (VEGF) in the central nervous system, J Biol Chem 277 (2002) 11410-11415. 10.1074/jbc.M111085200.
[38] H. Matsuzaki, M. Tamatani, A. Yamaguchi, K. Namikawa, H. Kiyama, M.P. Vitek, N. Mitsuda, M. Tohyama, Vascular endothelial growth factor rescues hippocampal neurons from glutamate-induced toxicity: signal transduction cascades, Faseb J 15 (2001) 1218-1220.
[39] K.L. Jin, Y.H. Zhu, Y.J. Sun, X.O. Mao, L. Xie, D.A. Greenberg, Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo, P Natl Acad Sci USA 99 (2002) 11946-11950. 10.1073/pnas.182296499.
[40] T. Kiuchi, H. Lee, T. Mikami, REGULAR EXERCISE CURES DEPRESSION-LIKE BEHAVIOR VIA VEGF-Flk-1 SIGNALING IN CHRONICALLY STRESSED MICE, Neuroscience 207 (2012) 208-217. 10.1016/j.neuroscience.2012.01.023.
[41] K. Fabel, K. Fabel, B. Tam, D. Kaufer, A. Baiker, N. Simmons, C.J. Kuo, T.D. Palmer, VEGF is necessary for exercise-induced adult hippocampal neurogenesis, Eur J Neurosci 18 (2003) 2803-2812. 10.1111/j.1460-9568.2003.03041.x.
[42] S. Zacchigna, D. Lambrechts, P. Carmeliet, Neurovascular signalling defects in neurodegeneration, Nat Rev Neurosci 9 (2008) 169-181. 10.1038/nrn2336.
[43] E. Storkebaum, P. Carmeliet, VEGF: a critical player in neurodegeneration, J Clin Invest 113 (2004) 14-18. 10.1172/Jci200420682.
[44] D. Lambrechts, P. Carmeliet, VEGF at the neurovascular interface: Therapeutic implications for motor neuron disease, Bba-Mol Basis Dis 1762 (2006) 1109-1121. 10.1016/j.bbadis.2006.04.005.
[45] B. Gurel, M. Cansev, C. Sevinc, S. Kelestemur, B. Ocalan, A. Cakir, S. Aydin, N. Kahveci, M. Ozansoy, O. Taskapilioglu, I.H. Ulus, M.K. Basar, B. Sahin, M.B. Tuzuner, A.T. Baykal, Early Stage Alterations in CA1 Extracellular Region Proteins Indicate Dysregulation of IL6 and Iron Homeostasis in the 5XFAD Alzheimer's Disease Mouse Model, Journal of Alzheimers Disease 61 (2018) 1399-1409. 10.3233/jad-170329.
[46] C. Franceschi, M. Capri, D. Monti, S. Giunta, F. Olivieri, F. Sevini, M.P. Panouraia, L. Invidia, L. Celani, M. Scurti, E. Cevenini, G.C. Castellani, S. Salvioli, Inflammaging and anti-inflammaging: A systemic perspective on aging and longevity emerged from studies in humans, Mechanisms of Ageing and Development 128 (2007) 92-105. 10.1016/j.mad.2006.11.016.
[47] C. Franceschi, Inflammaging as a major characteristic of old people: Can it be prevented or cured?, Nutrition Reviews 65 (2007) S173-S176. 10.1301/nr.2007.dec.S173-S176.
[48] C.A. Dinarello, Proinflammatory cytokines, Chest 118 (2000) 503-508. 10.1378/chest.118.2.503.
[49] D. Lindqvist, O.M. Wolkowitz, S. Mellon, R. Yehuda, J.D. Flory, C. Henn-Haase, L.M. Bierer, D. Abu-Amara, M. Coy, T.C. Neylan, L. Makotkine, V.I. Reus, X. Yan, N.M. Taylor, C.R. Marmar, F.S. Dhabhar, Proinflammatory milieu in combat-related PTSD is independent of depression and early life stress, Brain Behav Immun 42 (2014) 81-88. 10.1016/j.bbi.2014.06.003.
[50] L.P. Oganesyan, G.M. Mkrtchyan, S.H. Sukiasyan, A.S. Boyajyan, Classic and alternative complement cascades in post-traumatic stress disorder, Bull Exp Biol Med 148 (2009) 859-861. 10.1007/s10517-010-0836-0.
[51] S. Neelamekam, M. Nurjono, J. Lee, Regulation of interleukin-6 and leptin in schizophrenia patients: a preliminary analysis, Clin Psychopharmacol Neurosci 12 (2014) 209-214. 10.9758/cpn.2014.12.3.209.
[52] J. Mahadevan, A. Sundaresh, R.P. Rajkumar, A. Muthuramalingam, V. Menon, V.S. Negi, M.G. Sridhar, An exploratory study of immune markers in acute and transient psychosis, Asian J Psychiatr 25 (2017) 219-223. 10.1016/j.ajp.2016.11.010.
[53] E.A. Hoge, K. Brandstetter, S. Moshier, M.H. Pollack, K.K. Wong, N.M. Simon, Broad spectrum of cytokine abnormalities in panic disorder and posttraumatic stress disorder, Depress Anxiety 26 (2009) 447-455. 10.1002/da.20564.
[54] R. Ganguli, Z. Yang, G. Shurin, K.N. Chengappa, J.S. Brar, A.V. Gubbi, B.S. Rabin, Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness, Psychiatry Res 51 (1994) 1-10. 10.1016/0165-1781(94)90042-6.
[55] L. Durgadoss, P. Nidadavolu, R.K. Valli, U. Saeed, M. Mishra, P. Seth, V. Ravindranath, Redox modification of Akt mediated by the dopaminergic neurotoxin MPTP, in mouse midbrain, leads to down-regulation of pAkt, Faseb J 26 (2012) 1473-1483. 10.1096/fj.11-194100.
[56] F. Ahmad, P. Nidadavolu, L. Durgadoss, V. Ravindranath, Critical cysteines in Akt1 regulate its activity and proteasomal degradation: implications for neurodegenerative diseases, Free Radical Bio Med 74 (2014) 118-128. 10.1016/j.freeradbiomed.2014.06.004.
[57] F. Karege, A. Meary, N. Perroud, S. Jamain, M. Leboyer, E. Ballmann, R. Fernandez, A. Malafosse, F. Schurhoff, Genetic overlap between schizophrenia and bipolar disorder: A study with AKT1 gene variants and clinical phenotypes, Schizophr Res 135 (2012) 8-14. 10.1016/j.schres.2011.12.015.
[58] J.M. Devaney, H. Gordish-Dressman, B.T. Harmon, M.K. Bradbury, S.A. Devaney, T.B. Harris, P.D. Thompson, P.M. Clarkson, T.B. Price, T.J. Angelopoulos, P.M. Gordon, N.M. Moyna, L.S. Pescatello, P.S. Visich, R.F. Zoeller, R.L. Seip, J. Seo, B.H. Kim, L.L. Tosi, M. Garcia, R.L. Li, J.M. Zmuda, M.J. Delmonico, R.S. Lindsay, B.V. Howard, W.E. Kraus, E.P. Hoffman, AKT1 polymorphisms are associated with risk for metabolic syndrome, Hum Genet 129 (2011) 129-139. 10.1007/s00439-010-0910-8.
[59] A. Tramutola, J.C. Triplett, F. Di Domenico, D.M. Niedowicz, M.P. Murphy, R. Coccia, M. Perluigi, D.A. Butterfield, Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): analysis of brain from subjects with pre-clinical AD, amnestic mild cognitive impairment and late-stage AD, J Neurochem 133 (2015) 739-749. 10.1111/jnc.13037.
[60] H. Sancheti, G. Akopian, F. Yin, R.D. Brinton, J.P. Walsh, E. Cadenas, Age-Dependent Modulation of Synaptic Plasticity and Insulin Mimetic Effect of Lipoic Acid on a Mouse Model of Alzheimer's Disease, Plos One 8 (2013) e69830. 10.1371/journal.pone.0069830.
[61] Y. Liu, F. Liu, I. Grundke-Iqbal, K. Iqbal, C.X. Gong, Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes, Journal of Pathology 225 (2011) 54-62. 10.1002/path.2912.
[62] C. O' Neill, PI3-kinase/Akt/mTOR signaling: Impaired on/off switches in aging, cognitive decline and Alzheimer's disease, Experimental Gerontology 48 (2013) 647-653. 10.1016/j.exger.2013.02.025.
[63] F.-F. Liao, H. Xu, Insulin Signaling in Sporadic Alzheimer's Disease, Science Signaling 2 (2009) pe36. 10.1126/scisignal.274pe36.
[64] R. Avraham, Y. Yarden, Feedback regulation of EGFR signalling: decision making by early and delayed loops, Nat Rev Mol Cell Bio 12 (2011) 104-117. 10.1038/nrm3048.
[65] C. Berasain, M. Ujue Latasa, R. Urtasun, S. Goni, M. Elizalde, O. Garcia-Irigoyen, M. Azcona, J. Prieto, M.A. Avila, Epidermal Growth Factor Receptor (EGFR) Crosstalks in Liver Cancer, Cancers (Basel) 3 (2011) 2444-2461. 10.3390/cancers3022444.
[66] S. Siddiqui, M. Fang, B. Ni, D.Y. Lu, B. Martin, S. Maudsley, Central Role of the EGF Receptor in Neurometabolic Aging, Int J Endocrinol (2012). Artn 739428
10.1155/2012/739428.
[67] A. Farrugia, Albumin usage in clinical medicine: tradition or therapeutic?, Transfus Med Rev 24 (2010) 53-63. 10.1016/j.tmrv.2009.09.005.
[68] M.P. Margarson, N. Soni, Serum albumin: touchstone or totem?, Anaesthesia 53 (1998) 789-803. 10.1046/j.1365-2044.1998.00438.x.
[69] J. Lei, Y. Wang, X.Q. Guo, S.P. Yan, D.M. Ma, P.R. Wang, B.J. Li, W.J. Du, R.X. Guo, Q.C. Kan, Low preoperative serum ALB level is independently associated with poor overall survival in endometrial cancer patients, Future Oncology 16 (2020) 307-316. 10.2217/fon-2019-0732.
[70] H.M. Brown-Borg, A. Bartke, GH and IGF1: Roles in Energy Metabolism of Long-Living GH Mutant Mice, J Gerontol a-Biol 67 (2012) 652-660. 10.1093/gerona/gls086.
[71] N. Barzilai, D.M. Huffman, R.H. Muzumdar, A. Bartke, The Critical Role of Metabolic Pathways in Aging, Diabetes 61 (2012) 1315-1322. 10.2337/db11-1300.
[72] L. Perice, N. Barzilai, J. Verghese, E.F. Weiss, R. Holtzer, P. Cohen, S. Milman, Lower circulating insulin-like growth factor-I is associated with better cognition in females with exceptional Longevity without compromise to muscle mass and function, Aging-Us 8 (2016) 2414-2424. 10.18632/aging.101063.
[73] L. Katsouri, S. Georgopoulos, Lack of LDL receptor enhances amyloid deposition and decreases glial response in an Alzheimer's disease mouse model, PLoS One 6 (2011) e21880. 10.1371/journal.pone.0021880.
[74] J.M. Basak, P.B. Verghese, H. Yoon, J. Kim, D.M. Holtzman, Low-density lipoprotein receptor represents an apolipoprotein E-independent pathway of Abeta uptake and degradation by astrocytes, J Biol Chem 287 (2012) 13959-13971. 10.1074/jbc.M111.288746.
[75] L. Yao, X. Gu, Q. Song, X. Wang, M. Huang, M. Hu, L. Hou, T. Kang, J. Chen, H. Chen, X. Gao, Nanoformulated alpha-mangostin ameliorates Alzheimer's disease neuropathology by elevating LDLR expression and accelerating amyloid-beta clearance, J Control Release 226 (2016) 1-14. 10.1016/j.jconrel.2016.01.055.